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Patients with Stage 5 chronic kidney disease who have
hyperphosphatemia require treatment with phosphate
binders to lower serum phosphorus levels. Existing binders
are effective but may be associated with important safety
disadvantages. Lanthanum carbonate is a phosphate binder
with demonstrated efficacy, safety, and tolerability in clinical
trials. Changes in cognitive function were evaluated over
time using the Cognitive Drug Research computerized
cognitive assessment system (Simple Reaction Time, Digit
Vigilance Task, Choice Reaction Time, Numeric Working
Memory, and Delayed Picture Recognition) in 360
hemodialysis patients who were enrolled in a 2-year,
multicenter, comparative study of lanthanum carbonate
versus standard therapy. A decline in cognitive function from
baseline was observed in both groups. The deterioration
in cognitive function was similar in both the lanthanum
carbonate and standard therapy groups. One parameter –
Numeric Working Memory – showed a statistically significant
between-group difference in favor of lanthanum carbonate
(P¼ 0.02). Given the magnitude of the changes, however,
and the differences that were observed at baseline between
treatment groups, the clinical significance of this difference is
doubtful. This study demonstrates that cognitive function
deteriorates in hemodialysis patients over a 2-year time
period. Use of lanthanum carbonate as a phosphate binder
does not adversely affect cognitive function compared with
standard therapy.
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Hyperphosphatemia is a common complication seen in
patients with Stage 5 chronic kidney disease (CKD). Uncontrol-
led hyperphosphatemia contributes to the development
of secondary hyperparathyroidism, renal osteodystrophy,
and vascular calcification. The latter has also been linked
with an increased risk of cardiovascular mortality.1,2 To
reduce serum phosphorus levels, patients are treated with
phosphate-binding agents. A number of effective agents are
currently available, but all have certain disadvantages.
Calcium salts, including calcium carbonate and calcium
acetate, are currently the mainstay of therapy, but recent
evidence suggests that high doses of ingested calcium over
prolonged periods of time are associated with hypercalcemia
and vascular calcification.3,4 Sevelamer hydrochloride is a
non-calcium, non-aluminum phosphate binder that has
proven to be a useful addition to the current choices available.
There are, however, some concerns, including gastrointestinal
side effects, a tendency to metabolic acidosis, and a high pill
burden.5,6 A number of new agents are currently being
investigated but little is known about their long-term safety
and tolerability.7,8
Aluminum hydroxide is the most potent phosphate binder
that is currently available, but its toxic effects include brain
disease, bone disease, parathyroid suppression, and ane-
mia.9,10 The toxicity of aluminum in experimental animals
was first observed in 1897,11,12 with the earliest report in 1921
outlining similar effects in industrially exposed workers.13 In
1976, the link between aluminum exposure and encephalo-
pathy was first observed in dialysis patients.14 Abnormalities
in psychomotor function related to aluminum status have
been observed in hemodialysis patients even though they had
no overt clinical signs of aluminum toxicity.15
Studies of the cognitive effects in dialysis patients are
particularly relevant, as there is anecdotal evidence and cross-
sectional data to support a role for uremia and dialysis in
reducing cognitive function.16–20 Longitudinal data are
limited, although a study in elderly individuals found that
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those with CKD (glomerular filtration rate o60 ml/min/
1.73 m2) experienced a significantly greater decline in
cognitive function compared with those with preserved renal
function.20 In addition, it has been demonstrated that
cognitive brain dysfunction in hemodialysis patients may
be fully reversed by successful renal transplantation.16
Lanthanum carbonate (Fosrenols) is a phosphate binder
that is effective and well tolerated in patients with Stage 5
CKD21–24 and has similar phosphate-binding potency to
aluminum hydroxide (Damment SJP, Webster I, Presented at
the 36th Annual Meeting of the American Society of
Nephrology, San Diego, CA, USA, 2003). Importantly, the
bioavailability of lanthanum (0.00089%)25 is substantially
lower than that of aluminum (0.01%). There is no evidence
from animal studies that lanthanum can cross the blood–-
brain barrier.26,27 In fact, the impermeability of a number of
other blood–tissue barriers to lanthanum has also been
demonstrated, including the placenta and retina.28,29 No
functional or histopathological evidence of central nervous
system toxicity of lanthanum has been identified in oral or
intravenous studies with lanthanum carbonate in animals
(Damment SJP, Greaves P, Downes N, Presented at the 36th
Annual Meeting of the American Society of Nephrology, San
Diego, CA, USA, 2003; Jones C, Webster I, Damment SJP,
Presented at the 19th Congress of the ERA-EDTA, Lisbon,
Portugal, 2004). Although brain lanthanum deposition has
been reported recently in an animal model of renal failure,30
this finding has been challenged as a contamination artifact,31
as the mode of administration chosen (diet admixture)
carried a high risk of sample contamination during autopsy.
To allay fears about the potential for lanthanum to cause
cognitive dysfunction in a similar manner to aluminum, we
evaluated changes in cognitive function over time in hemo-
dialysis patients who were receiving lanthanum carbonate or
standard phosphate-binder therapy.
RESULTS
Patients
In total, 360 hemodialysis patients who were enrolled in the
cognitive function subgroup were randomized (lanthanum
carbonate, n¼ 179; standard therapy, n¼ 181) and per-
formed at least one on-study cognitive function testing
session. One hundred and thirty-three patients completed the
full 2 years of treatment. One hundred and twenty-four
patients (47 in the lanthanum carbonate group and 77 in the
standard therapy group) completed all six cognitive function
testing sessions. Notably, patient exposure was greater with
standard therapy (512 days) than with lanthanum carbonate
(366 days), as patients in the lanthanum carbonate group
were required to withdraw if adverse events occurred or the
investigator determined that additional therapy was required.
Patients randomized to standard therapy could change to
another approved phosphate binder or add additional
binders and still remain in the study.
Baseline characteristics and renal history are shown in
Table 1. The lanthanum carbonate and standard therapy
groups were well matched at baseline, with the exception of a
marginally higher proportion of Caucasian patients in the
lanthanum carbonate group. The baseline scores for the
Cognitive Drug Research (CDR) tests are presented in Table 2
as summary statistics of the major measures.
The median plasma lanthanum level in all patients at
screening was 0.0 ng/ml (range: 0.0–0.4 ng/ml). In patients
randomized to lanthanum carbonate, this rose to 0.3 ng/ml
(range: 0.0–3.1 ng/ml) by Week 7 and remained constant
thereafter. In patients who were randomized to standard
therapy, the median serum lanthanum level remained at
0.0 ng/ml (range: 0.0–2.7 ng/ml) throughout the study, except
at Month 18, at which time the median lanthanum level was
0.1 ng/ml (range: 0.0–0.2 ng/ml).
Concomitant medications
Before randomization, aluminum-based medications were
used by 12 patients (7%) who were subsequently randomized
to the lanthanum carbonate group and by eight patients (4%)
Table 1 | Baseline characteristics and renal history
Characteristic
Lanthanum
carbonate (n=179)
Standard therapy
(n=181)
Age, mean7s.d. (years) 54.4715.6 56.5714.1
Gender, n (%)
Male 104 (58) 109 (60)
Female 75 (42) 72 (40)
Race, n (%)
Caucasian 98 (55) 87 (48)
Black 68 (38) 73 (40)
Hispanic 10 (6) 15 (8)
Asian/Pacific 0 4 (2)
Native American 2 (1) 1 (1)
Other 1 (1) 1 (1)
Weight, mean7s.d. (kg) 80.2722.4 80.8719.5
Height, mean7s.d. (cm) 169.9711.4 171.7710.9
Primary renal diagnosis, n (%)
Diabetes 52 (29) 62 (34)
Hypertension 59 (33) 44 (24)
Glomerulonephritis 20 (11) 26 (14)
Cystic kidney disease 10 (6) 10 (6)
Urologic disease 1 (1) 4 (2)
Unknown cause 5 (3) 3 (2)
Other known cause 32 (18) 32 (18)
Previous kidney transplant, n (%)
No 150 (84) 1678 (92)
Yes 29 (16) 14 (8)
Duration on hemodialysis (years)
Median 2.82 2.37
Range 0.4–19.4 0.4–21.8
Previous treatment, n (%)
Calcium acetate 76 (43) 75 (41)
Calcium carbonate 50 (28) 60 (33)
Not listed 1 (1) 3 (2)
Other therapy 7 (4) 6 (3)
Sevelamer hydrochloride 44 (25) 37 (20)
Kidney International (2007) 71, 252–259 253
P Altmann et al.: Lanthanum carbonate does not affect cognition o r i g i n a l a r t i c l e
who entered the standard therapy group. Psychotropic drugs
(e.g. antidepressants, antipsychotics or mood-stabilizing
agents) were used by 85 patients (47%) who were
subsequently randomized to the lanthanum carbonate group
and 69 patients (38%) who were randomized to the standard
therapy group. During the study, aluminum-containing
medications were used by 20 patients (11%) in the
lanthanum carbonate group and by 20 patients (11%) in
the standard therapy group. These medications included
aluminum hydroxide and aluminum carbonate, and were
generally prescribed over the short term for the treatment of
dyspepsia, nausea, and chest pain, as well as for hyperpho-
sphatemia. During the study, psychotropic drugs were used
by 109 patients (61%) in the lanthanum carbonate group and
104 patients (58%) in the standard therapy group. Acetyl
cholinesterase inhibitors, which are used for the maintenance
of cognitive function in patients with Alzheimer’s disease,
were used before and after randomization by two patients
(1%) in the standard therapy group. At baseline, vitamin D
and analogues were used by 42% of patients in the
lanthanum carbonate group and 44% of patients in the
standard therapy group. During the study, vitamin D and
analogues were used by 39% of patients in the lanthanum
carbonate group and 48% of patients in the standard therapy
group.
Results from mixed effect model for repeated measures
Differences in cognitive function between the two treatment
arms (lanthanum carbonate and standard therapy) were
noted at the baseline (screening) assessment (Table 2). This
difference showed a uniform pattern of performance being
consistently poorer in the standard therapy than in the
lanthanum carbonate arm. This was seen both in longer
reaction times in the standard therapy arm on each task and
in poorer accuracy scores (sensitivity indices, percentage
accuracy, and false-alarm scores).
Cognitive function declined for most tests in both
treatment groups over 2 years of treatment (Table 3, ‘Visit’
column). In addition, there were some other points of
interest from these model fits. For the measure of Digit
Vigilance – Targets Detected, there was a significant
treatment-by-visit interaction (P¼ 0.027; Table 3; Figure 1),
indicating a different rate of decline between the two
treatment groups. Although this interaction was influenced
by a marked deterioration at the Final Visit in the standard
therapy group, there were also greater deteriorations at Visits
9, 12, and 15 for standard therapy, which contributed to the
Table 2 | Baseline scores on the CDR tasks
Lanthanum
carbonate (n=174)
Standard therapy
(n=178)
Simple Reaction Time (ms)
Mean 378.0 423.1
95% CI 362.2, 397.7 393.6, 452.5
Digit Vigilance – targets detected (%)
Mean 92.7 90.7
95% CI 91.2, 94.2 88.7, 92.7
Digit Vigilance – response time (ms)
Mean 486.2 503.5
95% CI 475.4, 497.1 491.6, 515.4
Digit Vigilance – false alarms (#)
Mean 1.90 2.12
95% CI 1.54, 2.25 1.70, 2.55
Choice Reaction Time – accuracy (%)
Mean 96.6 96.2
95% CI 95.9, 97.2 95.4, 97.0
Choice Reaction Time – response time (ms)
Mean 600.2 641.8
95% CI 579.9, 620.5 614.4, 669.2
Numeric Working Memory – sensitivity Indexa
Mean 0.88 0.83
95% CI 0.85, 0.90 0.80, 0.86
Numeric Working Memory – response time (ms)
Mean 1067 1137
95% CI 1011, 1122 1073, 1201
Picture Recognition – sensitivity index
Mean 0.59 0.54
95% CI 0.55, 0.62 0.50, 0.57
Picture Recognition – response time (ms)
Mean 1377 1461
95% CI 1301, 1452 1380, 1541
CDR, Cognitive Drug Research; CI, confidence interval; SI, sensitivity index.
aSI combines the ability to identify previously presented items correctly and to reject
those that were not previously presented. The score represents the overall ability of
the patient to recognize (or be sensitive to) the task information (1=perfect
discrimination; 0=chance performance).32
Table 3 | P-values from the mixed effect model
Parameter Treatmenta Visitb Treatment-by-Visit Interactionc
Simple Reaction Time (ms) 0.4520 0.0024* 0.2725
Digit Vigilance – targets detected (%) 0.0275* 0.0141* 0.0269*
Digit Vigilance – response time (ms) 0.6949 0.0001* 0.4772
Choice Reaction Time – response time (ms) 0.1681 0.0001* 0.0352*
Numeric Working Memory – sensitivity index (SI) 0.1288 0.0886 0.6424
Numeric Working Memory – response time (ms) 0.0243* 0.1169 0.8846
Picture Recognition – SI 0.2911 0.0372* 0.2625
Picture Recognition – response time (ms) 0.7612 0.8701 0.1646
*Statistically significant.
aA significant treatment effect indicates a difference in overall effect between the two groups.
bA significant visit effect indicates an overall change (deterioration in this case) over time.
cA significant treatment by visit interaction indicates a different rate of decline between the two treatment groups.
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treatment effect. These comparisons supported a benefit for
lanthanum carbonate over standard therapy at the Final Visit
only and any interpretation of these differences should
consider both differences at baseline and the differential
completion rates between the treatment groups.
There was no significant difference between the declines in
Choice Reaction Time seen between the treatment groups
(P¼ 0.17; Figure 2), although there was a significant
treatment-by-visit interaction (P¼ 0.035). This was clearly
a result of the difference between values at the Final Visit
only. Accuracy scores showed little change over time
(median: 0).
Response time, measured in milliseconds (ms), increased
(i.e. deteriorated) on the Numeric Working Memory task in
both treatment groups. This decline was greater in the
standard therapy group (Figure 3), with an overall significant
treatment effect in favor of lanthanum carbonate (P¼ 0.02).
The magnitude of treatment difference was, however, small
compared with the baseline between-group difference of
88 ms.
A complete summary of results from the mixed effects
model is presented in Table 3.
DISCUSSION
Overall, this study shows that patients with Stage 5 CKD on
hemodialysis who received either lanthanum carbonate or
standard therapy experienced deterioration in cognitive
function over 2 years. Notably, the impairments in cognitive
function were generally related to the speed of task
completion: whereas patients’ accuracy in completing the
tests did not decline substantially, tests took longer to
complete as the study progressed. The decline seen in the
present study is consistent with previous studies that have
shown significant impairments in cognitive function in
patients with CKD compared with normal populations16–18
and the available longitudinal data showing that the decline
in cognitive function over time is marked compared with that
expected as a result of normal aging.20 For example,
deterioration in patients receiving dialysis compared with
healthy individuals has been reported in a cross-sectional
study.16 Cognitive function in that study was assessed using
visual-evoked potentials, which have previously been shown
to correlate with the Symbol Digit Coding Test of
psychomotor function.15 The level of deterioration was
similar to that observed on the CDR assessment system in
the present study.16
Moreover, the decline can be halted, and even reversed, by
transplantation,16 suggesting a major role for uremia (and
possibly the dialysis process itself) in the decline; however,
factors such as vascular disease and subclinical Alzheimer’s
disease cannot be ruled out. Importantly, cognitive decline in
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Figure 1 | Digit Vigilance Task – targets detected (%)
(least-squares means795% CI from mixed effect model).
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(least-squares means795% CI from mixed effect model).
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dialysis patients, which is not always appreciated by
nephrologists in the clinic, can have an impact on issues
such as the ability to remain employed, compliance with
medication, decision-making, and attendance at clinic
appointments.
Despite the similarities in baseline demographic charac-
teristics, baseline CDR response time measurements were
statistically significantly better in the lanthanum carbonate
group (e.g., for Choice Reaction Time, a difference of around
50 ms was observed). This could not have been the result of a
breakdown in randomization, as the baseline CDR assess-
ment was carried out during screening, before patients were
randomized. In an attempt to explain this baseline difference,
several factors that are known to affect cognitive function
were investigated. At baseline, similar proportions of patients
were receiving aluminum-based medications or active
vitamin D (or analogues). A numerically higher percentage
of patients in the lanthanum carbonate group were receiving
psychotropic drugs at baseline, although agents such as
diazepam and temazepam might be expected to have an
adverse effect on cognitive function. Post hoc analysis of
summary statistics separated by psychiatric medical history
or by patients’ race did not explain the baseline difference
(data not shown). Hematocrit values were also compared
between groups in a post hoc analysis and were not considered
to be clinically important (data not shown). There are a
number of other possible explanations for a baseline
difference in cognitive function, such as level of athero-
sclerosis, adequacy of dialysis, geographical differences,
educational level, or socioeconomic effects. Insufficient data
are available for exploratory analyses of these factors. How-
ever, the differences, along with the variability of the scores at
baseline, are not considered to be clinically important
and therefore would not have affected the outcomes of
the study.
Cognitive deterioration over time was the same in the
lanthanum carbonate and standard therapy groups. The only
parameter that has an independent significant difference
between the treatment groups was Numeric Working
Memory (P¼ 0.02 in favor of lanthanum carbonate). This
should, however, be interpreted with caution because the
magnitude of treatment difference was small, when compared
with the baseline between-group difference. In addition,
significant treatment-by-time interactions were seen for Digit
Vigilance (targets detected) and Choice Reaction Time
(response time). These, however, appear to be spurious
results that are related to the effects at a single time point that
were not consistent throughout treatment.
There have been conflicting reports about the extent to
which lanthanum is able to cross the blood–brain barrier. In
detailed electron microscopy studies in rats, lanthanum was
unable to penetrate intercellular tight junctions or pass
through the endothelial cells of the blood–brain barrier.26,27
Consistent with this, bulk brain lanthanum concentrations in
various animal studies, measured using Inductively Coupled
Plasma Mass Spectrometry (ICP-MS), were below quantifi-
able limits33 and toxicology studies identified no adverse
effects of lanthanum carbonate treatment on brain function
or histology (Damment SJP, Greaves P, Downes N, Presented
at the 36th Annual Meeting of the American Society of
Nephrology, San Diego, CA, USA, 2003; Jones C, Webster I,
Damment SJP, Presented at the 19th Congress of the ERA-
EDTA, Lisbon, Portugal, 2004). Recently, Lacour et al.30
reported elevated levels of lanthanum in an adenine rat
model of chronic renal failure. Surprisingly, no increase in
brain concentration occurred after treatment with lanthanum
carbonate in an alternative renal failure model (5/6th
nephrectomized) or in normal rats in the same study, both
of these groups having numerically lower brain concentra-
tions compared with their respective untreated controls.
Subsequently, the findings of this study have been challenged
as a contamination artifact.31 Lanthanum carbonate was
offered to the rats in a powdered diet at 3% w/w, and thus
entered the animals’ environment at concentrations at least
six orders of magnitude higher than in normal brain,
presenting a high risk of tissue contamination at autopsy,
whereas lanthanum in previous studies was gavaged directly
into the stomach of the rats.
The computer-controlled tasks from the CDR cognitive
assessment system chosen for the present study are those
focusing on attention, working memory, and reaction time,
and it should be noted that their ability to assess episodic
memory and other aspects of cognition are limited. Indeed,
memory is often tested through the use of multiple learning
trials and free recall trials. The effects of dialysis treatment on
other aspects of cognitive function such as list learning or
symbol digit replacement are not well studied. The CDR tests
are sensitive measures of psychomotor function that are more
appropriate for investigational studies than for routine
clinical use. A number of groups have investigated simpler
methods of assessing cognitive function that are appropriate
for dialysis patients. One such method is the Kidney Disease
Quality of Life Cognitive Function Subscale. This is a self-
report measure that includes a 36-item health survey as the
generic core, supplemented with scales that are targeted at
particular concerns of individuals with kidney disease and
receiving dialysis. In a validation study in patients with CKD,
a high level of correlation was demonstrated between the
Kidney Disease Quality of Life Cognitive Function Subscale
and the modified Mini-Mental State Examination (MMSE).19
The modified MMSE is considered to be more sensitive than
the traditional MMSE, especially for mild cognitive change.
The modified MMSE incorporates four added test items,
more graded scoring, and other minor changes. These
modifications are designed to sample a broader variety of
cognitive functions, cover a wider range of difficulty levels,
and enhance the reliability and the validity of the scores.34 As
reported elsewhere,35 when the MMSE was administered to
dialysis patients receiving either lanthanum carbonate or
standard therapy, the mean score on the MMSE at baseline
was 28.4 (a normal MMSE score is considered to be 424) in
both treatment groups, and no changes were seen over 2 years
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of treatment. Although normal in this study, the MMSE has
been found to be abnormal when broadly applied to
hemodialysis patients.36,37 As a tool for assessing cognitive
function in selected groups of patients, however, the MMSE
is not sufficiently discriminatory. This emphasizes the need
for further refinement of tools for assessing cognitive
impairment in CKD. As these defects may be at least partially
reversible,16 appropriate treatment of cognitive function
deterioration may be possible. This applies to patients with
CKD Stages 3 and 4, as well as those with Stage 5 CKD
receiving hemodialysis.17 Among the abnormalities that are
thought to be responsible for the defects in cognition,
cerebrovascular disease,18 anemia,38 and disorders of mineral
metabolism39 stand out.
Conclusions
Hemodialysis patients who were treated with lanthanum
carbonate and standard phosphate binders showed deteriora-
tion in cognitive function during 2 years of follow-up. This
deterioration was marked compared with normal aging and
was independent of the phosphate-binder therapy that was
used. There is no known mechanism for lanthanum to cross
the blood–brain barrier, and no toxic effects of lanthanum in
brain or other tissues have been observed in studies of
animals exposed to large doses of lanthanum. Thus, it seems
unlikely that lanthanum carbonate poses a similar threat of
neurotoxicity to that observed with the far more readily
absorbed aluminum from aluminum-hydroxide-containing
phosphate binders. Lanthanum carbonate remains effective
and well tolerated for the treatment of patients with
hyperphosphatemia in Stage 5 CKD.
MATERIALS AND METHODS
Study design
Cognitive function assessment was conducted at 41 sites in the USA
in a subgroup of hemodialysis patients from a 2-year, randomized,
open-label comparator study of lanthanum carbonate versus
standard therapy.35 The study comprised three phases: screening
and a 1–3-week washout period of previous phosphate binders; a
6-week dose titration period; and long-term maintenance (up to
2 years’ total study participation). Patients were randomized 1:1 to
receive lanthanum carbonate or their pre-study phosphate binder.
Lanthanum carbonate treatment was started at a dose of 750 or
1500 mg/day, at the discretion of the investigator. The dose could be
titrated up to 3000 mg/day or down to 375 mg/day, as necessary.
Table 4 | List of CDR assessments
Task Description Major measure
Supporting
measurea
Attentional Tasks:
Simple Reaction Time The patient was instructed to press the ‘YES’ response button as
quickly as possible every time the word ‘YES’ was presented on the
monitor. Thirty stimuli were presented at varying interstimulus
intervals.
Response time (ms)
Digit Vigilance A target digit was randomly selected and constantly displayed to the
right of the monitor screen. A series of digits was presented in the
center of the screen at the rate of 150 per minute, and the patient
was required to press the ‘YES’ button as quickly as possible every
time the digit in the series matched the target digit. In total, 450
digits, including 45 targets, were presented over 3 min.
Response time (ms)
Targets detected (%)
False alarms (#)
Choice Reaction Time Either the word ‘NO’ or the word ‘YES’ was presented on the monitor
and the patient was instructed to press the corresponding button as
quickly as possible. Thirty trials were chosen randomly with equal
probability, and were presented at varying interstimulus intervals.
Response time (ms) Accuracy (%)
Working Memory Task:
Numeric Working
Memory
A series of five digits was presented for the patient to remember,
followed by a series of 30 probe digits. For each digit, the patient
indicated whether or not they recognized it as being from the
original series by pressing the ‘YES’ or ‘NO’ button as appropriate.
Sensitivity index (SI)b
Response time (ms)
Episodic Secondary Memory Task:
Picture Recognition Before the Simple Reaction Time test, a series of 20 pictures was
presented on the monitor at the rate of one every 3 seconds for the
patient to remember. In the Picture Recognition test, the original
pictures, plus 20 distracter pictures, were presented one at a time in
a randomized order. For each picture, the patient indicated whether
or not they recognized it as being from the original series by
pressing the ‘YES’ or ‘NO’ button as appropriate.
Sensitivity index (SI)b
Response time (ms)
aAnalysis of covariance was not carried out on the supporting measures.
bSI combines the ability to identify previously presented items correctly and to reject those that were not previously presented. The score represents the overall ability of the
patient to recognize (or be sensitive to) the task information (1=perfect discrimination; 0=chance performance).32
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Patients in the standard therapy group could switch or add other
phosphate binders at the discretion of the investigator throughout
the study.
Patients
All patients were 18 years of age or older and had received hemo-
dialysis three times per week for Stage 5 CKD for at least 2 months
before enrolment. All patients were judged by the investigator to
have the initiative, health, and means to be compliant with the study
protocol.
Patients were excluded if they had clinically significant abnormal
laboratory values at screening, unless they were considered to be a
consequence of Stage 5 CKD. Patients receiving psychotropic drugs
who had been stabilized for less than 1 month were also excluded.
Other exclusion criteria included documented aluminum-related
bone disease or dementia, a screening calcium level below 7.9 mg/dl
(1.98 mmol/l), evidence of previous gastrointestinal surgery or
ongoing gastrointestinal disorders, levels of serum transaminases
more than three times the upper limit of normal, life-threatening
malignancy or current multiple myeloma, known HIV-positive
status, or exposure to an experimental drug within 30 days before
screening. Pregnant or lactating women, and women of reproductive
potential, who did not agree to use effective birth control methods,
were also excluded.
Assessments
Cognitive function was assessed using computer-controlled tasks
from the CDR cognitive assessment system (Table 4). This method
was chosen because a reproducible and objective assessment of
cognitive function could be quickly administered by a research
nurse. Information was presented on high-resolution monitors, and
responses were recorded via response modules containing two
buttons, one marked ‘NO’ and the other marked ‘YES’. During the
screening period, patients received two training sessions, each
consisting of two administrations of the testing system. Patients who
did not successfully complete the training sessions after two
attempts were excluded from the study, whereas those patients
who completed the training then received a baseline assessment.
Testing was performed before dialysis at the second or third dialysis
session of the week. Tests were carried out at screening (pre-
randomization/baseline), 3.5 months (Visit 9), 6 months (Visit 12),
12 months (Visit 15), 18 months (Visit 18), and 24 months
(Final Visit). For patients who terminated the study early, the last
testing session was included in the appropriate time category, rather
than as Final Visit. Patients were recruited for the cognitive function
sub-study before randomization into a treatment group in an
attempt to avoid potential bias. The tests were conducted in the
order outlined in Table 4. The first three tasks were tests of the
patient’s attention span; the last two tasks were tests of the patient’s
memory.
Analysis
Summary statistics were calculated for each measure and each time-
point by treatment. For each of the major measures, a mixed effects
model for repeated measures was used to examine the difference
from baseline data. Fixed terms in the model were treatment, time-
point and treatment-by-time-point interaction. A random effect of
subjects-within-treatment was included in the model and baseline
score was used as a covariate. Analyses were conducted on the
intent-to-treat population, which was defined as all patients who
were randomized and had at least one post-randomization
phosphorus measurement in the main study.
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